Cite this answer
Exenatide: quick citable summary
Exenatide is listed by PeptaHub as a weight loss peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Exenatide: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/exenatide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/exenatide.
What is Exenatide?
Exenatide is a synthetic version of exendin-4 from Gila monster venom and was the first FDA-approved GLP-1 receptor agonist (2005). It was sold as twice-daily Byetta and once-weekly Bydureon for type 2 diabetes, but AstraZeneca discontinued all US exenatide products in 2024.
Overview
Exenatide is a synthetic version of exendin-4, a naturally occurring peptide found in the venom of the Gila monster lizard. The first GLP-1 receptor agonistreceptor agonist approved by the FDA (2005), it shares approximately 50% amino acid homology with human GLP-1. Available as twice-daily Byetta and once-weekly extended-release Bydureon, it was a foundational type 2 diabetes therapy for nearly two decades, though AstraZeneca discontinued Byetta and all Bydureon products in the US in late 2024.
Mechanism of action
Exenatide binds and activates the glucagon-like peptide-1 receptor (GLP-1R), a G-protein coupled receptor expressed on pancreatic beta cells, gut, brain, heart, and kidneys. Activation triggers glucose-dependent insulin secretion via cAMP-PKA and Epac2 signaling, suppresses inappropriately elevated glucagon from pancreatic alpha cells, and slows gastric emptying—collectively blunting postprandial glucose excursions. Unlike native GLP-1 (half-life ~2 min), exenatide resists degradation by dipeptidyl peptidase-4 (DPP-4) due to an alanine-to-glycine substitution at position 2. Central GLP-1R activation in the hypothalamus and brainstem reduces appetite and increases satiety, contributing to the weight loss observed clinically.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| type 2 diabetes glycemic control (Byetta) | subcutaneous | 5–10 mcg | twice daily | Start at 5 mcg BID for 1 month, then increase to 10 mcg BID if tolerated. Inject 60 minutes before morning and evening meals. |
| type 2 diabetes glycemic control (Bydureon) | subcutaneous | 2–2 mg | once weekly | Fixed dose of 2 mg once weekly. No titration required. Rotate injection site. Extended-release microsphere formulation. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Exenatide research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Exenatide dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
Pivotal AMIGO trials (2004–2005) demonstrated HbA1c reductions of 0.8–1.1% and weight loss of 2–3 kg vs. placebo over 30 weeks in type 2 diabetes. The DURATION-1 trial showed a 1.9% HbA1c reduction with once-weekly Bydureon, greater than the 1.5% seen with twice-daily Byetta. Unlike some GLP-1 agents, cardiovascular outcome data (EXSCEL trial, 14,752 patients) showed noninferiority but not superiority for major adverse cardiovascular events vs. placebo.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Exenatide for synergistic effects.
Legal status
FDA-approved since April 2005 (Byetta) and January 2012 (Bydureon BCise) as an adjunct to diet and exercise for type 2 diabetes mellitus. AstraZeneca discontinued Byetta and all Bydureon products in the US in October 2024, so branded exenatide is no longer commercially available in the US as of 2026. Contraindicated in patients with a prior severe hypersensitivity reaction to exenatide or its excipients and in those with a history of drug-induced immune-mediated thrombocytopenia from exenatide products. Not recommended in end-stage renal disease or severe renal impairment (creatinine clearance below 30 mL/min). Off-label use for obesity was common but declined as newer agents (semaglutide, tirzepatide) entered the market.
Sourcing & access
Prescription required
Exenatide is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster lizard. It was the first GLP-1 receptor agonist approved by the FDA and is sold as Byetta and Bydureon.
Exenatide binds and activates the GLP-1 receptor on pancreatic beta cells, triggering glucose-dependent insulin secretion. It also suppresses inappropriately elevated glucagon and slows gastric emptying. An alanine-to-glycine substitution at position 2 makes it resistant to DPP-4 degradation.
Yes — exenatide was FDA-approved in April 2005 as Byetta and in January 2012 as Bydureon BCise, indicated for type 2 diabetes as an adjunct to diet and exercise. AstraZeneca discontinued Byetta and all Bydureon products in the US in October 2024, so branded exenatide is no longer marketed in the US.
Byetta is started at 5 mcg twice daily subcutaneously for 1 month, then increased to 10 mcg twice daily if tolerated, injected 60 minutes before the morning and evening meals. Bydureon is a fixed 2 mg once-weekly dose with no titration required.
The most common side effects are gastrointestinal: nausea (usually transient), vomiting, and diarrhea. Hypoglycemia can occur when combined with sulfonylureas, and rare reports include acute pancreatitis, renal impairment, and a GLP-1 class warning for medullary thyroid carcinoma risk from animal data.
Byetta has a half-life of approximately 2.4 hours, which is why it requires twice-daily dosing. Bydureon has an apparent half-life of about 2 weeks because of its extended-release microsphere formulation.
Exenatide is a short-acting exendin-4 analog with roughly 50% homology to native GLP-1, while semaglutide is a long-acting human GLP-1 analog. Semaglutide has largely superseded exenatide for weight loss due to superior efficacy and simpler dosing.
Research references
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesPubMed
- Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesPubMed
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1)PubMed
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)PubMed